These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35959355)

  • 1. Physical Therapy for at Least 6 Months Improves Motor Symptoms in Parkinson's Patients: A Meta-Analysis.
    Ji X; Lu D; Yang Q; Xiao L; Wang J; Wang G
    Comput Math Methods Med; 2022; 2022():3393191. PubMed ID: 35959355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Long-Term Physiotherapy in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Okada Y; Ohtsuka H; Kamata N; Yamamoto S; Sawada M; Nakamura J; Okamoto M; Narita M; Nikaido Y; Urakami H; Kawasaki T; Morioka S; Shomoto K; Hattori N
    J Parkinsons Dis; 2021; 11(4):1619-1630. PubMed ID: 34366377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of virtual reality versus motor imagery versus routine physical therapy in patients with parkinson's disease: a randomized controlled trial.
    Kashif M; Albalwi AA; Zulfiqar A; Bashir K; Alharbi AA; Zaidi S
    BMC Geriatr; 2024 Mar; 24(1):229. PubMed ID: 38443801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).
    Clarke CE; Patel S; Ives N; Rick CE; Woolley R; Wheatley K; Walker MF; Zhu S; Kandiyali R; Yao G; Sackley CM
    Health Technol Assess; 2016 Aug; 20(63):1-96. PubMed ID: 27580669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up.
    Mansouri A; Taslimi S; Badhiwala JH; Witiw CD; Nassiri F; Odekerken VJJ; De Bie RMA; Kalia SK; Hodaie M; Munhoz RP; Fasano A; Lozano AM
    J Neurosurg; 2018 Apr; 128(4):1199-1213. PubMed ID: 28665252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PD-Ballet study: study protocol for a randomised controlled single-blind hybrid type 2 clinical trial evaluating the effects of ballet dancing on motor and non-motor symptoms in Parkinson's disease.
    Podlewska AM; Batzu L; Soukup T; Sevdalis N; Bakolis I; Derbyshire-Fox F; Hartley A; Healey A; Woods A; Crane N; Pariante C; Ray Chaudhuri K
    BMC Complement Med Ther; 2024 Jan; 24(1):41. PubMed ID: 38233784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori eradication for Parkinson's disease.
    Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiotherapy versus placebo or no intervention in Parkinson's disease.
    Tomlinson CL; Patel S; Meek C; Herd CP; Clarke CE; Stowe R; Shah L; Sackley CM; Deane KH; Wheatley K; Ives N
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD002817. PubMed ID: 24018704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of moderate aerobic exercise for patients with Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.
    Li Y; Song H; Shen L; Wang Y
    Ann Palliat Med; 2021 Mar; 10(3):2638-2649. PubMed ID: 33549003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.